A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease
Latest Information Update: 19 Nov 2025
At a glance
- Drugs TEV 53408 (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 19 Nov 2025 New trial record